image credit: Unsplash

2022 forecast: We wish we had better news for biotech dealmaking in 2022, but omicron is coming anyway

December 22, 2021


We thought we’d finally get to see what a post-pandemic world looked like in 2022, but thanks to omicron, it seems we’re in for another round.

Biotech has been shaped by the pandemic in ways that may be permanent, just as every industry has. Key among the changes is how deals are struck and an explosion of research into treatments and vaccines for COVID-19.

Let’s start with the deals. Instead of executives sneaking off to corners of conference halls, these days, it’s Zoom meetings and cold calls. We heard over the past year that deals slowed down as chance encounters at events such as the annual J.P. Morgan Healthcare Conference stopped.

Read More on FierceBiotech